Hope you can find a way to kick the habit. Smoking is linked to endothelial disfunction, vasoconstriction, and faster MS disease progression- just not good on any level- yes, it affects bloodflow by causing nitric oxide disruption.
Smoking and Disease Progression in Multiple Sclerosis
Brian C. Healy, PhD; Eman N. Ali, MD; Charles R. G. Guttmann, MD; Tanuja Chitnis, MD; Bonnie I. Glanz, PhD; Guy Buckle, MD; Maria Houtchens, MD; Lynn Stazzone, MSN, NP; Jennifer Moodie, MD; Annika M. Berger, MD; Yang Duan, MD; Rohit Bakshi, MD; Samia Khoury, MD; Howard Weiner, MD; Alberto Ascherio, MD
Arch Neurol. 2009;66(7):858-864.
Background Although cigarette smokers are at increased risk of developing multiple sclerosis (MS), the effect of smoking on the progression of MS remains uncertain.
Objective To establish the relationship between cigarette smoking and progression of MS using clinical and magnetic resonance imaging outcomes
Design Cross-sectional survey and longitudinal follow-up for a mean of 3.29 years, ending January 15, 2008.
Setting Partners MS Center (Boston, Massachusetts), a referral center for patients with MS.
Patients Study participants included 1465 patients with clinically definite MS (25.1% men), with mean (range) age at baseline of 42.0 (16-75) years and disease duration of 9.4 (0-50.4) years. Seven hundred eighty patients (53.2%) were never-smokers, 428 (29.2%) were ex-smokers, and 257 (17.5%) were current smokers.
Main Outcome Measures Smoking groups were compared for baseline clinical and magnetic resonance imaging characteristics as well as progression and sustained progression on the Expanded Disability Status Scale at 2 and 5 years and time to disease conversion to secondary progressive MS. In addition, the rate of on-study change in the brain parenchymal fraction and T2 hyperintense lesion volume were compared.
Results: Current smokers had significantly worse disease at baseline than never-smokers in terms of Expanded Disability Status Scale score (adjusted P < .001), Multiple Sclerosis Severity Score (adjusted P < .001), and brain parenchymal fraction (adjusted P = .004). In addition, current smokers were significantly more likely to have primary progressive MS (adjusted odds ratio, 2.41; 95% confidence interval, 1.09-5.34). At longitudinal analyses, MS in smokers progressed from relapsing-remitting to secondary progressive disease faster than in never-smokers (hazard ratio for current smokers vs never-smokers, 2.50; 95% confidence interval, 1.42-4.41). In addition, in smokers, the T2-weighted lesion volume increased faster (P = .02), and brain parenchymal fraction decreased faster (P = .02).
Conclusion Our data suggest that cigarette smoke has an adverse influence on the progression of MS and accelerates conversion from a relapsing-remitting to a progressive course.
Husband dx RRMS 3/07
dx dual jugular vein stenosis (CCSVI) 4/09
dual stents placed 5/09
CCSVI in MS